Skip to main content
Jeffrey E. Lancet on Muck Rack

Jeffrey E. Lancet

As seen in: Leukemia, Nature, Wiley Online Library, Cancer Investigation, MDPI, JAMA Oncology, The Lancet, HemOnc Today, AACR Journal, HMP Global Learning Network and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeffrey E.

Contact Jeffrey E., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Optimizing Decision-Making on Transplantation for Patients With AML

|
By Jeffrey E. Lancet
| Oncology Learning Network Verified
At the 2026 LL&M Winter Symposium, Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, Florida discussed the latest clinical insights into determining which patients with acute myeloid leukemia (AML) should be recommended for transplant. Transcript: I'm Jeff Lancet from the Moffitt Cancer Center in Tampa, Florida. I am here at the LL&M Winter Symposium on Hematologic Malignancies. I was asked to speak today about how to optimize decision-making for transplant in AML.
Open in Who Shared Issue with article?

Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients

|
By Christopher Dukes, Jeffrey E. Lancet, Barbara J. Kuter, Marine Potez
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Integrative molecular subtypes of acute myeloid leukemia - Blood Cancer Journal

|
By Qianxing Mo, Seongseok Yun, David A Sallman, Jeffrey E. Lancet
| Nature Verified
Dear Editor, AML is a heterogenous disease characterized by distinct clinical courses and prognoses based on genomic, epigenomic and transcriptomic profiles [1, 2]. Therefore, molecular classification and risk stratification are essential for clinical decision. Although cytogenetics is one of the most powerful prognostic indicators in AML, more than 50% of AML patients have normal karyotypes.
Open in Who Shared Issue with article?
See all 17 articles